Moderna has found a replacement for ousted CFO Jorge Gomez, announcing Wednesday that PerkinElmer executive James Mock will be its next finance chief.
The appointment of Mock comes several months after Moderna hired and then quickly fired Gomez from the role after it became known Gomez’ former employer, dental equipment manufacturer Dentsply Sirona, was investigating “certain financial reporting matters.”
Mock has served as CFO at PerkinElmer, a large life sciences and diagnostics firm, since 2018, overseeing several small acquisitions as well as a roughly $5.3 billion takeover of antibody and reagent provider BioLegend last year. On Aug. 1, PerkinElmer announced plans to divest its food and enterprise services division to a private equity firm for almost $2.5 billion.
Prior to PerkinElmer, Mock worked for nearly two decades at General Electric. READ MORE
By Ned Pagliarulo
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.